Effects of Reduced Mir-24 Expression on Plasma Methotrexate Levels, Therapy-Related Toxicities, and Patient Outcomes in Pediatric Acute Lymphoblastic Leukemia.
Acute Lymphoblastic Leukemia
Event Free Survival
Methotrexate
Mir
Toxicity
Journal
Reports of biochemistry & molecular biology
ISSN: 2322-3480
Titre abrégé: Rep Biochem Mol Biol
Pays: Iran
ID NLM: 101637937
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
ppublish
Résumé
The current study aims to investigate the relationship of miR-24 expression with plasma methotrexate (MTX) levels, therapy-related toxicities, and event-free survival (EFS) in Iranian pediatric acute lymphoblastic leukemia (ALL) patients. The study included 74 ALL patients in consolidation phase and 41 healthy children. RNA was extracted from plasma, polyadenylated, and reverse transcribed. miR-24 expression was determined by quantitative polymerase chain reaction (qPCR). Plasma MTX concentrations were measured by high performance liquid chromatography (HPLC) 48 h after high-dose methotrexate (HD-MTX) injection. The diagnosis of ALL was further subclassified as B-ALL or T-ALL via flow cytometry. miR-24 expression was less in pediatric ALL patients than in the control group (p = 0.0038). Furthermore, downregulation of miR-24 was correlated with intermediate- to high-grade HD-MTX therapy toxicities (p = 0.025). Nevertheless, no statistically significant associations were seen between miR-24 levels and plasma MTX levels 48 h after HD-MTX administration (p > 0.05) or EFS in pediatric ALL patients (p > 0.05). miR-24 expression may contribute to interindividual variability in response to intermediate- to highgrade HD-MTX therapy toxicities under Berlin Frankfurt Munster (BFM) treatment.
Sections du résumé
BACKGROUND
BACKGROUND
The current study aims to investigate the relationship of miR-24 expression with plasma methotrexate (MTX) levels, therapy-related toxicities, and event-free survival (EFS) in Iranian pediatric acute lymphoblastic leukemia (ALL) patients.
METHODS
METHODS
The study included 74 ALL patients in consolidation phase and 41 healthy children. RNA was extracted from plasma, polyadenylated, and reverse transcribed. miR-24 expression was determined by quantitative polymerase chain reaction (qPCR). Plasma MTX concentrations were measured by high performance liquid chromatography (HPLC) 48 h after high-dose methotrexate (HD-MTX) injection. The diagnosis of ALL was further subclassified as B-ALL or T-ALL via flow cytometry.
RESULTS
RESULTS
miR-24 expression was less in pediatric ALL patients than in the control group (p = 0.0038). Furthermore, downregulation of miR-24 was correlated with intermediate- to high-grade HD-MTX therapy toxicities (p = 0.025). Nevertheless, no statistically significant associations were seen between miR-24 levels and plasma MTX levels 48 h after HD-MTX administration (p > 0.05) or EFS in pediatric ALL patients (p > 0.05).
CONCLUSION
CONCLUSIONS
miR-24 expression may contribute to interindividual variability in response to intermediate- to highgrade HD-MTX therapy toxicities under Berlin Frankfurt Munster (BFM) treatment.
Types de publication
Journal Article
Langues
eng
Pagination
358-365Références
PLoS One. 2013;8(1):e55406
pubmed: 23383180
Br J Cancer. 2017 Sep 5;117(6):801-812
pubmed: 28787435
Am J Pathol. 2017 Jun;187(6):1343-1355
pubmed: 28432871
N Engl J Med. 2005 Oct 27;353(17):1793-801
pubmed: 16251535
Blood. 2008 May 15;111(10):5078-85
pubmed: 18337557
J Cell Biochem. 2019 Aug;120(8):12966-12976
pubmed: 31001849
Pediatr Blood Cancer. 2012 Oct;59(4):599-604
pubmed: 22492670
Ann Hematol. 2018 Jul;97(7):1169-1182
pubmed: 29556721
Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13513-8
pubmed: 17686970
Leuk Lymphoma. 2011 Jun;52(6):1030-40
pubmed: 21534867
World J Gastroenterol. 2019 Apr 7;25(13):1580-1591
pubmed: 30983818
Eur J Clin Pharmacol. 2014 Mar;70(3):253-60
pubmed: 24370659
Blood. 2008 Mar 15;111(6):3183-9
pubmed: 18187662
Oncol Rep. 2015 Apr;33(4):1639-49
pubmed: 25672522
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5
pubmed: 17293455
Bone Marrow Res. 2012;2012:406796
pubmed: 22852088
Yonsei Med J. 2017 Jul;58(4):697-702
pubmed: 28540980
Blood. 2008 Jan 15;111(2):588-95
pubmed: 17906079
J Exp Clin Cancer Res. 2015 Aug 22;34:86
pubmed: 26297223
Oncotarget. 2018 Feb 5;9(16):12868-12878
pubmed: 29560116
Pharmacogenomics. 2014 Aug;15(11):1479-94
pubmed: 25303299
Oncotarget. 2017 Mar 21;8(12):19507-19521
pubmed: 28061479
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6
pubmed: 18056805
Cancer Clin Trials. 1978 Summer;1(2):107-11
pubmed: 316368
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Int J Clin Exp Pathol. 2014 Oct 15;7(11):8032-8
pubmed: 25550847